Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Jul;7(2):81-6.
doi: 10.3904/kjim.1992.7.2.81.

Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis

Y W Cho  1 , D H Yang, D Y Oh, S H Baick, S K Kim, S J Kim, S Y Hong
Affiliations

Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis

Y W Cho et al. Korean J Intern Med. 1992 Jul.

Abstract

Basal plasma tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAl-1) antigen levels were studied in 49 non-insulin dependent diabetic patients (23 men, 26 women: ages 51.3 +/- 14.9 years) and 16 age matched non-diabetic subjects (9 men, 7 women: ages 49.8 +/- 12.2 years) as a control group. Compared to a control group, the diabetic patients had a significantly higher mean t-PA antigen (5.15 +/- 3.02 vs 3.20 +/- 2.30 ng/ml) and PAl-1 antigen (35.89 +/- 18.59 vs 17.60 +/- 15.36 ng/ml) levels (p < 0.05). Plasma t-PA antigen level was not influenced by each treatment modality. There was a significant decrease of plasma PAl-1 antigen level after Metformin administration compared to that of before Metformin administration (39.74 +/- 19.39 vs 25.14 +/- 16.18 ng/ml) (p < 0.05), and the insulin-treated group showed a tendency for a decrease of plasma PAl-1 antigen levels after insulin administration but this did not reach statistical significance (29.93 +/- 15.37 vs 17.32 +/- 10.60 ng/ml). Sulfonylurea did not change both plasma t-PA and PAl-1 antigen levels. In conclusion, diabetic patients have high t-PA and PAl-1 antigen levels. Biguanide reduced plasma PAl-1 antigen levels, which might play some helpful role in the improvement of chronic complications in NIDDM.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Comparison of t-PA and PAI-1 antigen levels diabetic and non-diabetic subjects.
Fig. 2.
Fig. 2.
Changes of plasma PAI-1 antigen level according to treatment modality.
See this image and copyright information in PMC

References

    1. Crofford OB. The long-range plan to combined diabetes. Vol. 1. US Department of Health, Education and Welfare, Public Health Service, National Institute of Health; 1976. Report of the National Commission on Diabetes. Publication NO. (NIH) 76-1018.
    1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381. - PubMed
    1. Almer LO. Fibrinolytic disorders in diabetes mellitus. Diabete & Metabolism. 1988;14:519.
    1. Auwerx J, Bouillon R, Collen D, Goboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988;8:68. - PubMed
    1. Fearnley GR, Chakrabarti R, Avis PR. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischemic heart disease and obesity. Brit Med J. 1963;1:921. - PMC - PubMed

MeSH terms